RU-58841 vs finasteride vs minoxidil: what each one actually does, and what it costs you

These three names get set side by side as if they were three brands of the same thing: three bottles on a shelf, pick one. They are not the same kind of object at all.

Two of them are medicines. They have been through trials with thousands of men, regulators have approved them, and we know a great deal about what happens when you use them for years. The third is a research compound. It has never completed a large human trial, and it is approved nowhere on earth.

We make the third one. We're telling you at the top anyway, because a comparison that quietly flattens that difference isn't a comparison. It's an advertisement wearing a lab coat.

Most men arrive here with two fears pulling against each other: losing more hair while they decide, and paying for their hair with something worse. Both are reasonable. Here is the fair version, so you can weigh them properly.

First: they are not doing the same job

Androgenetic alopecia runs on one chain. Your testosterone is converted by 5-alpha-reductase into DHT. DHT binds the androgen receptor inside genetically susceptible follicles. The follicle's growth phase is cut short, and the hair it makes gets thinner and shorter with every cycle until it covers nothing.

We take that apart properly in why you are losing your hair: DHT, the androgen receptor, and what actually stops it. What matters here is that each of these three attacks a different link in the chain:

• Finasteride stops the DHT being made.
• RU-58841 aims to occupy the receptor, so the DHT that is made can't deliver its message.
• Minoxidil ignores the hormone entirely and pushes growth from further down the line.

They are not rivals. They are three different tools, and "which one is best" is close to meaningless until you say what you're trying to do, and what you're willing to trade.

Finasteride: the brake, at the factory

What it does. Finasteride inhibits type 2 5-alpha-reductase, the enzyme that converts testosterone into DHT. At the standard dose it cuts circulating DHT by roughly two thirds, and scalp DHT substantially.

Dutasteride, its bigger sibling, inhibits both enzyme types and suppresses DHT further. It is prescribed for hair loss in some countries and used off-label in others.

The evidence. This is where honesty costs us something. Finasteride has the strongest evidence base of anything in this field, by a wide margin: large randomised placebo-controlled trials, five-year follow-up, replicated across populations, measured with hair counts rather than vibes. In those trials the majority of men stopped losing ground, and a substantial minority visibly gained some.

If your only question is "what is most likely to work, according to the best data that exists", the answer is finasteride. We're not going to dress that up.

The trade. It is systemic. You swallow it, and DHT falls everywhere, not only in the follicles you care about. That is the entire reason a market for topical antiandrogens exists at all.

On a cycle? Read why finasteride fails against most steroids, and what to run instead.

Side effects, handled honestly. In the trials, sexual side effects (reduced libido, erectile difficulty, ejaculatory changes) were reported at a few percent, and the gap over placebo was a couple of percentage points. Small. Also real.

Separately, some men report symptoms that did not resolve after stopping. This is discussed as post-finasteride syndrome. It is contested in the literature and its mechanism is not established, but it has been reflected in regulatory labelling changes in more than one jurisdiction.

The trial numbers are real. So is the man in the thread. A trial describes what happened to a population; you are one person, and the population figure can't tell you which person you will be. Anyone who resolves that tension for you, in either direction, is doing it for their own convenience, not yours.

It is a prescription medicine. Whether the trade is right for you is a conversation for a doctor, not for a vendor and not for a forum.

RU-58841: the lock, jammed

What it does. RU-58841 is a nonsteroidal androgen receptor antagonist, CAS 154992-24-2. It does not lower your DHT. It competes for the receptor that DHT needs to bind.

If RU-58841 is occupying the seat, the hormone arrives to find it taken, and the instruction to cut the growth phase short is never transmitted.

It came out of Roussel-Uclaf, and it was designed from the start to be applied to skin: to act on the receptor where it lands, and to be broken down rather than build up systemically. In animal models, including primate models of androgenetic hair loss, it did what it was designed to do, with local activity and without the systemic antiandrogenic effect a swallowed antiandrogen would produce.

Then it stopped. It never became an approved medicine. Why development ended is not publicly documented in any form we would defend.

You'll find confident explanations on forums and vendor websites. They are guesses, and usually guesses that flatter whoever is telling them.

The evidence. This is the whole of it, stated without softening:

• There are no large human trials. None. Not buried, not old, not foreign-language. They were not run.
• There is no long-term human safety data, because generating it requires the trial that was not run.
• It is approved nowhere, for anything.
• What exists in humans is anecdote: forum logs, photographs, self-reports. Some of it is careful and honest. It is still anecdote, and it can't tell you a rate (how often something works, how often something goes wrong), which is the only thing a trial is for.

Side effects. Unknown. Not "none": unknown, which is a different and more uncomfortable word. Community reports run in both directions, including reports of systemic antiandrogenic symptoms at higher exposures.

Anyone who tells you RU-58841 is free of side effects is telling you something they cannot know. We go through what side effects are actually reported in a separate article.

So why do men choose it? Because the reasoning is legible. They want the androgen signal interrupted at the follicle without suppressing DHT throughout their body, and RU-58841 is the best-known compound in that category.

Put simply: finasteride lowers DHT across your whole body, and that's where its sexual side effects come from. Folliva DHT Blocker blocks DHT at the follicle's receptor without lowering your DHT or your testosterone, which is why there are no sexual side effects. Your body keeps its DHT. The follicle just stops listening.

That is a rational thing to want. Whether it delivers in humans, at what rate and at what cost, is exactly what has never been established. If you use it, you are accepting an evidence gap in exchange for a route of administration, and you should know that is the trade.

Minoxidil: the accelerator

What it does. Minoxidil is a potassium channel opener with vasodilatory effects. After decades of use, the honest summary of how it works in hair is still "not completely understood". What it demonstrably does is lengthen the growth phase, wake resting follicles, and increase the diameter of the hair a follicle produces.

One detail matters more than the rest: minoxidil is a prodrug. It has to be converted in the scalp into minoxidil sulfate by an enzyme, sulfotransferase, and men vary a great deal in how much of that enzyme their follicles express.

That is the leading explanation for why some men respond to minoxidil and some, applying it identically for a year with total discipline, get nothing. They didn't do it wrong. The conversion step didn't happen.

The evidence. Strong and old. Approved and over the counter in topical form in most of the world. Increasingly used orally at low dose, off-label, under medical supervision, which is a conversation for a doctor.

Side effects. Scalp irritation and flaking, very often caused by the propylene glycol in the vehicle rather than the drug itself; foam formulations exist for exactly this reason. Unwanted hair growth where the solution runs or gets transferred, particularly the face. A shed in the first weeks, which looks like a disaster and isn't one: the month-by-month timeline linked below explains why.

Oral minoxidil carries systemic cardiovascular considerations and is not a DIY decision. Minoxidil is also seriously toxic to cats, which is worth knowing if you have one.

What it cannot do. It never touches the hormone, the enzyme or the receptor. The DHT signal continues, uninterrupted, the entire time.

It is the accelerator, not the brake. You end up growing hair into a headwind.

That is why minoxidil alone so often plateaus, and why men who spent two years on it alone feel cheated. They weren't doing it wrong. It was never fighting the cause, only compensating for it, and compensation loses eventually.

The comparison, in one table

	Finasteride	RU-58841	Minoxidil
Target	5-alpha-reductase (the enzyme)	The androgen receptor	Downstream growth, no androgen target
Effect on your DHT	Lowers it, body-wide	Does not lower it. Blocks its receptor at the follicle	None
Route	Oral, systemic	Topical	Topical (oral off-label)
Regulatory status	Approved medicine, prescription	None. Research compound	Approved, over the counter
Human evidence	Large RCTs, 5-year data	No large human trials	Large RCTs, decades of use
Known side-effect profile	Characterised: low rates in trials, contested persistent reports	Not characterised in humans	Characterised: irritation, unwanted hair, initial shed
What it cannot do	Stay local	Show you a trial	Touch the cause

Read the bottom row again. Those are the three real costs, and every man in this field is choosing which of them he can live with.

Do they combine?

By mechanism, obviously yes. RU-58841 and minoxidil share no target: one is trying to silence a signal, the other is trying to extend a growth phase. Stacking them isn't a marketing invention. It's what the chain implies.

The same logic is why ketoconazole shampoo turns up in almost every protocol as the cheap third leg: a small anti-androgenic and anti-inflammatory action at the scalp for the price of a shampoo. We cover it in ketoconazole shampoo: the DHT blocker hiding in the shampoo aisle.

Now the honest half of the answer: nobody has run the combination trial. No study tells you RU-58841 plus minoxidil is additive, or safe together over five years, or better than either alone.

The logic is sound. The data does not exist. Those are two different statements, and we won't let one stand in for the other.

What we can be held to

We can't show you a trial. Nobody can. What we can show you is the bottle.

Folliva DHT Blocker is RU-58841 at 5%, blended by us in the EU, in small batches. It is not bought in and not rebottled. The batch number, the blend date and the expiry are printed on the bottle, so you always know how old the thing in your hand is. For a compound that degrades with time and light, that is not a detail.

It ships from inside the EU: days rather than weeks, in a plain box that tells nobody anything.

Weighing raw powder against a ready-made solution? Read RU58841 powder vs pre-made solution: cost, stability, and what actually reaches your scalp. Buying from anyone, anywhere? Start with what to check before you order RU58841 in Europe.

We can be held to what is in the bottle and how it reached you. We can't promise what it will do for your hair, and we won't pretend otherwise. See the full range.

How to actually choose

Not a recommendation. A decision frame. You make the call, ideally with a doctor.

• If your priority is the best-evidenced outcome, and a doctor agrees a systemic medicine is reasonable for you: finasteride is the most evidenced thing on this page. It is not what we sell. It is still the honest answer to that question.
• If your priority is a topical with real trials behind it: minoxidil, understanding that it is the accelerator and does not address the cause.
• If your priority is interrupting the androgen signal at the follicle without a systemic 5-alpha-reductase inhibitor: that is the category RU-58841 sits in, and you are trading away the evidence base to be there. Go in knowing that, or don't go in.
• If you want the cheapest sensible thing tonight: a ketoconazole shampoo, with actual contact time. It is a leg, not the table.

One thing is true of all three, and it is the least popular sentence in this industry: none of them is a cure. Each works, to the extent it works, only while you keep using it. Stop, and the follicles resume the trajectory they were on.

The cause was never removed, only opposed. That isn't a subscription trap. It's what "the cause is still there" means.

Whichever you choose, you can't judge it by looking in the mirror and feeling hopeful or doomed. Six months is the earliest point a fair judgement is possible, and it has to be made against photographs. We wrote the month-by-month version here: the hair loss timeline, and why most people quit at week three.

What to do now

You now know what each option does and what each one costs. The harder question is which trade fits you: how far your hair loss has gone, what you've already tried, and what you're not willing to risk.

Start there. Take the 2-minute hair analysis: a few questions about your hair loss, so you can see where you stand before you spend anything.

If Folliva DHT Blocker turns out to be your fit, your first order comes with a 120-day money-back guarantee. Think of it as a free trial: if it isn't for you, email us within 120 days of delivery, send the bottle back (opened is fine), and we refund your first order in full.

Then give it the time the biology needs. Photos on day one, a fair verdict at six months. Every month DHT keeps working, more follicles shrink, so the earlier you stop it, the more hair you keep.

---

Folliva Labs formulates topical research compounds in the EU. This article describes published mechanism and evidence. It is not medical advice, not a comparison of medicines for the purpose of recommending one, and not a claim that any product prevents, treats or cures any condition.

Finasteride and minoxidil are medicines: discuss them with a doctor. RU-58841 is sold for laboratory research: not for human or veterinary use.